Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda

East African Medical Journal

Volumn 76, Issue 6, 1999, Pages 307-313

  Bwire, R ^a,b   Borgdorff, M W ^b   Sticht Groh, V ^c   Rieder, H L ^d   Kawuma, H J S ^a   Bretzel, G ^c   Rusch Gerdes S ^e  

^a St Francis Leprosy Centre   (Uganda)

^b KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^c Klinikum der Ludwig Maximilians Universität München   (Germany)

^d Tuberculosis Division of IUATLD   (Switzerland)

^e RESEARCH CENTER BORSTEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AFRICA; AFRICA SOUTH OF THE SAHARA; AIDS RELATED COMPLEX; ANTIBIOTICS--THERAPEUTIC USE; ARTICLE; COMPARATIVE STUDY; DEVELOPING COUNTRY; DISEASES; DRUG COMBINATION; DRUG RESISTANCE; EASTERN AFRICA; ENGLISH SPEAKING AFRICA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTIONS; LUNG TUBERCULOSIS; MALE; METHODOLOGY; MICROBIOLOGY; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY; RESEARCH REPORT; SERODIAGNOSIS; SPUTUM; STUDIES; SURVIVAL; TREATMENT; TREATMENT OUTCOME; TUBERCULOSIS; UGANDA; VIRAL DISEASES;

AFRICA; AFRICA SOUTH OF THE SAHARA; ANTIBIOTICS--THERAPEUTIC USE; DEVELOPING COUNTRIES; DISEASES; DRUGS; EASTERN AFRICA; ENGLISH SPEAKING AFRICA; HIV INFECTIONS; INFECTIONS; PROSPECTIVE STUDIES; RESEARCH METHODOLOGY; RESEARCH REPORT; STUDIES; TREATMENT; TUBERCULOSIS; UGANDA; VIRAL DISEASES;

ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HIV SERONEGATIVITY; HIV SEROPREVALENCE; HUMANS; ISONIAZID; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRAZINAMIDE; RIFAMPIN; SPUTUM; STREPTOMYCIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; UGANDA;

EID: 0033139919     PISSN: 0012835X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Nunn, P., Kibuga, D., Gathua, S et al. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet. 1991; 337: 627.
2. Murray, C.J.L., Styblo, K. and Rouillon, A. Tuberculosis in developing countries: burden, intervention and cost. Bull. IUATLD. 1990; 65: 5.
3. Nelles, A. Das Kulturverfahren in der Tuberkulosediagnostik. Die Vorbehandlung von infiziertem Untersuchungsmaterial. In: Meissner G. & Schmieder A ed. Mykobakterien und mykobakterielle krankheiten. Teil IV: Laboratoriumsdiagnose der mykobkterien, Gustav Fischer Verlag, Jena, 1968; Germaṅy, 75-117.
4. Kubica, G.P. and Pool, G.L. Studies on the catalase activity of acid-fast bacilli. I. An attempt to subgroup these organisms on the basis of their catalase activity at different temperature and pH. Am. Rev. Respir. Dis. 1969; 81: 387.
5. Colebunders,. R.L., Ryder, R.W., Nzilambi, N. et al. HIV infection in patients with tuberculosis in Kinshasa, Zaire. Am. Rev. Respir. Dis. 1989; 139: 1082.
6. Small, P.M., Schecter, G.F., Goodman, P.C. et al. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 1991; 324: 289.
7. Telzak, E.E., Fazal, B.A., Pollard, C.L. et al. Factors influencing time to sputum conversion among patients with smear-positive pulmonary tuberculosis. Clin. Infect. Dis. 1997; 25: 666.
8. Brindle, R.J., Nunn, P.P., Githui, W. et al. Quantitative bacillary response to treatment in HIV-associated pulmonary tuberculosis. Am. Rev. Respir. Dis. 1993; 147: 958.
9. China Tuberculosis Control Collaboration. Results of directly observed short-course chemotherapy in 112, 842 Chinese patients with smear-positive tuberculosis. Lancet. 1996; 347: 358.
10. Ledru, S., Cauchoix, B., Yameogo, M. et al. Impact of short-course therapy on tuberculosis drug resistance in South-West Burkina Faso. Tuber. Lung. Dis. 1996; 77: 429.
11. Githui, W., Nunn, P., Juma, E. et al. Cohort study of HIV-positive and HIV-negative tuberculosis, Nairobi, Kenya: comparison of bacteriological results. Tuber. Lung. Dis. 1992; 73: 203.
12. Asch, S., Knowles, L., Rai, A., Jones, B.E., Pogoda, J. and Barnes, P.F. Relationship of isoniazid resistance to human immunodeficiency virus infection in patients with tuberculosis. Am. J. Respir. Crit. Care Med. 1996; 153: 1708.
13. Shafer, R.W., Chirgwin, K.D., Glatt, A.E. et al. HIV prevalence, immunosuppression, and drug resistance in patients with tuberculosis in an area endemic for AIDS. AIDS. 1991; 5: 399.
14. Frieden, T.R., Sterling, T., Pablos-Mendez, A. et al. The emergence of drug-resistant tuberculosis in New York city. N. Engl. J. Med. 1993; 328: 521.
15. De Cock, K.M., Soro, B., Coulibaly, I.M. and Lucas, S.B. Tuberculosis and HIV infection in sub-Saharan Africa. J. Amer. Med. Ass. 1992; 268: 1581.
16. Cantwell, M.F. and Binkin, N.J. Impact of HIV on tuberculosis in sub-Saharan Africa: a regional perspective. Int. J. Tuberc. Lung. Dis. 1997; 1: 205.
17. Elliot, A.M., Halwiindi, B., Hayes, R.J. et al. The impact of human immunodeficiency virus on presentation and diagnosis of tuberculosis in a cohort study in Zambia. J. Trop. Med. Hyg. 1993; 96: 1.
18. Ackah, A.N., Coulibaly, D., Digbeu, H. et al. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Cote d'Ivoire. Lancet. 1995; 345: 607.
19. Nunn, P, Brindle, L., Carpenter, J. et al. Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya: analysis of early (six-month) mortality. Am. Rev. Respir. Dis. 1992; 146: 849.